Summary

Symptoms of cardiotoxicity resulting from cancer therapy, sometimes manifesting years or even decades later, are a problem for survivors. In a special session on cardio-oncology, expert consensus recommendations from the European Association of Cardiovascular Imaging on best practices for detecting signs of cardiotoxicity in cancer survivors were reviewed.

  • multimodality imaging
  • cardiotoxicity
  • radiotherapy
  • chemotherapy
  • radiation-induced heart disease
  • cardiovascular risk
  • trastuzumab
  • anthracycline
  • monoclonal antibody
  • tyrosine kinase inhibitor
View Full Text